Skip to content

A study to evaluate Performance and Safety of the Bactiguard Central Venous Catheter in seriously ill patients

A Multicenter, Randomized, Parallel group, Open label, Post Marketing Clinical Investigation Study to assess efficacy and safety of Bactiguard® Central Venous Catheter (CVC) Compared to Standard Central Venous Catheter (CVC) in Critically ill Patients

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/05/052947
Enrollment
500
Registered
2023-05-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Bactiguard Central Venous Catheter (CVC): upto 14 days Control Intervention1: Standard Central Venous Catheter (CVC): Upto 14 Days

Sponsors

Bactiguard AB
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female patients of age between 18 to 75 years both inclusive. 2. Patients hospitalised in intensive care units expected to require indwelling central venous catheterization for = 3 days (jugular vein, subclavian vein, femoral vein). 3. Patients or his/her legally authorized representative (if applicable) who are willing to sign informed consent for participation in the study and willing to adhere to all protocol procedures.

Exclusion criteria

Exclusion criteria: 1. Patients with suspected catheter related infections. 2. Patients receiving an initial study catheter through guide wire exchange. 3. Patients with malignant diseases and unlikely to survive for the next 28 days in the opinion of the intensive care unit consultant; 4. Patients hospitalised for severe burn injuries; 5. Patient with a history of thrombocytopenia 6. Patient with a history of bleeding disorders 7. Patient with signs of infection, wounds and subcutaneous haematoma close to the puncture site 8. Patients with, in the opinion of the investigator, a situation that is not suitable for indwelling placement, including allergy to the catheter material, confirmed deep vein thrombosis and abnormal anatomical structure post-surgical changes in the insertion site. 9. Current enrolment in a clinical study of any other unapproved investigational intravenous device within 30 days prior to signing informed consent. 10. Female patients who are pregnant or lactating.

Design outcomes

Primary

MeasureTime frame
Incidence of central line–associated bloodstream infection (CLABSI)Timepoint: 14 Days

Secondary

MeasureTime frame
The incidence of CVC related adverse events (AEs) and severe adverse events (SAEs) from baseline to end of study.Timepoint: 14 Days;Incidence of catheter-related thrombosis [Time Frame: From central venous catheter insertion until date of catheter removal]Timepoint: 14 Days;Duration of Stay in the Intensive Care Unit (ICU).Timepoint: 14 Days;Duration of HospitalizationTimepoint: 14 Days

Countries

India

Contacts

Public ContactDr Neeta Nargundkar

Biosphere Clinical Research Pvt. Ltd

drneeta@biospherecro.com02241006794

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026